“Non-canonical FLT3 mutations in Acute Myeloid Leukemia: Implications for Therapy and Prognosis”

Amy S. Duffield, M.D., Ph.D.
Professor of Pathology, Icahn School of Medicine at Mount Sinai
Director of Hematopathology

At the conclusion of this activity, the participant will be able to:

1. Review the molecular and clinical ramifications of fms-like tyrosine kinase 3 (FLT3) mutations in acute myeloid leukemia
2. Describe the role of FLT3 inhibition in the treatment of FLT3-mutated acute myeloid leukemia
3. Discuss the importance of a multidisciplinary approach in the optimal treatment of patients

Accreditation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System is accredited by the Accreditation Council for Continuing Medical Education (ACCME®) to provide continuing medical education for physicians.

Credit Designation: VCU Health Continuing Medical Education of Virginia Commonwealth University Health System designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Financial Relationships:
The following planners, moderators or speakers have the following financial relationship(s) with commercial interests to disclose: Nothing to disclose